Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Multi-Panel, Single Oral Rising-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of MK0822 in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Odanacatib (Primary)
- Indications Male osteoporosis; Postmenopausal osteoporosis
- Focus Adverse reactions; Biomarker
- Sponsors Merck Sharp & Dohme Corp.
- 24 Mar 2009 New trial record